<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03099798</url>
  </required_header>
  <id_info>
    <org_study_id>NL54542.028.16 / P1609</org_study_id>
    <nct_id>NCT03099798</nct_id>
  </id_info>
  <brief_title>Traumatic Splenic Injury and Management (SPLENIQ Study)</brief_title>
  <acronym>SPLENIQ</acronym>
  <official_title>Traumatic Splenic Injury and Management (SPLENIQ Study) Quality of Life and Clinical Outcomes of Treatment for Splenic Injury After Trauma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elisabeth-TweeSteden Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maasstad Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Albert Schweitzer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amphia Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Tilburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medisch Spectrum Twente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Isala</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Elisabeth-TweeSteden Ziekenhuis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVE:&#xD;
&#xD;
      To determine the quality of life (QOL) and clinical outcome after conservative therapy,&#xD;
      embolization (proximal versus distal) or surgery in patients with traumatic splenic injury.&#xD;
      Secondary aims: (I) to examine therapy-related complications, (II) to establish the necessity&#xD;
      of additional therapies, (III) the assessment of splenic function related to splenic&#xD;
      morphology (MR imaging) after embolization and (IV) to find the prognostic factors for&#xD;
      failure of non-operative management (NOM) in patients with splenic injuries. Finally, with&#xD;
      the acquired data from this study a patient-oriented protocol will be provided for the&#xD;
      management of traumatic splenic injury.&#xD;
&#xD;
      HYPOTHESIS:&#xD;
&#xD;
      The investigators expect that NOM is superior to surgery with regard to QOL, clinical outcome&#xD;
      and splenic function. Embolization will need more additional therapies. Splenic morphology is&#xD;
      related to splenic immune function. Expected prognostic factors are age above 40, ISS &gt;25 and&#xD;
      a splenic injury grade of 3 or higher.&#xD;
&#xD;
      STUDY DESIGN:&#xD;
&#xD;
      A combination of a retrospective and a prospective multicentre cohort study. This protocol&#xD;
      involves the prospective part of the study.&#xD;
&#xD;
      STUDY POPULATION/DATASET:&#xD;
&#xD;
      Patients who enter the participating hospitals between March 2017 and December 2018 with&#xD;
      splenic injury will be asked to participate. The follow-up period will be one year with&#xD;
      regard to QOL, clinical symptoms and imaging.&#xD;
&#xD;
      INTERVENTION:&#xD;
&#xD;
      All patients will complete a number of questionnaires at different time points. The patients&#xD;
      who were treated with splenic artery embolization (SAE) will undergo an MRI one month and one&#xD;
      year after treatment.&#xD;
&#xD;
      OUTCOME MEASURES:&#xD;
&#xD;
      Primary outcome is QOL. Secondary outcomes are clinical symptoms and imaging.&#xD;
&#xD;
      SAMPLE SIZE:&#xD;
&#xD;
      Approximately 100 patients will be included per year during the inclusion phase.&#xD;
&#xD;
      DATA ANALYSIS:&#xD;
&#xD;
      With regard to the prospective data linear modelling will be performed.&#xD;
&#xD;
      COLLABORATION/CONNECTION:&#xD;
&#xD;
      Tilburg University, Erasmus Medical Center Rotterdam, Maasstad Hospital Rotterdam, Albert&#xD;
      Schweitzer Hospital Dordrecht, Amphia hospital Breda, Leiden University Medical Center, VU&#xD;
      University Medical Center Amsterdam, Medical Spectrum Twente, Radboud University Nijmegen,&#xD;
      Isala Zwolle.&#xD;
&#xD;
      TIME SCHEDULE:&#xD;
&#xD;
      Year 1: literature search and conducting the retrospective study and analyses. Years 1-3:&#xD;
      inclusion prospective study and follow-up of patients. Year 4: finishing follow-up data&#xD;
      collection and analysing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life: baseline (within 1 week after treatment)</measure>
    <time_frame>One week after treatment</time_frame>
    <description>WHOQoL-Bref questionnaire, SF-12 and EQ-5D-5L questionnaires</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life: 1 month follow-up</measure>
    <time_frame>One month after treatment</time_frame>
    <description>WHOQoL-Bref questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life: 3 months follow-up</measure>
    <time_frame>Three months after treatment</time_frame>
    <description>WHOQoL-Bref questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life: 6 months follow-up</measure>
    <time_frame>Six months after treatment</time_frame>
    <description>WHOQoL-Bref questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life: one year follow-up</measure>
    <time_frame>One year after treatment</time_frame>
    <description>WHOQoL-Bref questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in health status: SF-12</measure>
    <time_frame>One week, 1 month and 3, 6 and 12 months after treatment</time_frame>
    <description>SF-12 questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in health related quality of life: EQ-5D-5L</measure>
    <time_frame>One week, 1 month and 3, 6 and 12 months after treatment</time_frame>
    <description>EQ-5D-5L questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome</measure>
    <time_frame>One year follow-up</time_frame>
    <description>Data obtained from the patient records (e.g. complications, need for re-intervention, hospital stay, return to daily activities)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>One year follow-up</time_frame>
    <description>The overall cost-effectiveness will be assessed with the iPCQ and iMCQ questionnaires, completed at different time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging Outcome after Embolization (one month after treatment)</measure>
    <time_frame>One month after embolization</time_frame>
    <description>Splenic morphological characteristics (e.g. volume, necrosis, splenosis, calcifications or chronic infarction morphology)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging Outcome after Embolization (one year after treatment)</measure>
    <time_frame>One year after embolization</time_frame>
    <description>Splenic morphological characteristics (e.g.volume, necrosis, splenosis, calcifications or chronic infarction morphology)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Splenic Artery Embolization characteristics</measure>
    <time_frame>One year follow-up</time_frame>
    <description>Difference between proximal versus distal embolization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic factors for failure of Non-Operative Management</measure>
    <time_frame>One year follow-up</time_frame>
    <description>A recent study suggests that there are prognostic factors for failure of NOM in the treatment of adults with (blunt) splenic injury. Strong evidence exists for: age of 40 years or above, Injury Severity Score (ISS) of 25 or greater and American Association for the Surgery of Trauma (AAST) splenic injury grade of 3 or greater.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">106</enrollment>
  <condition>Quality of Life</condition>
  <condition>Spleen Injury</condition>
  <condition>Trauma</condition>
  <condition>Splenic Artery Embolization</condition>
  <arm_group>
    <arm_group_label>Non-Operative Management (NOM)/Observational</arm_group_label>
    <description>Patients &quot;treated&quot; observationally for (traumatic) spleen injury.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Splenic Artery Embolization</arm_group_label>
    <description>Patients treated with splenic artery embolization for (traumatic) spleen injury.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <description>Patients treated surgically for (traumatic) spleen injury.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>All patients will complete a number of questionnaires at different time points.&#xD;
SF-12, WHOQoL-Bref, EQ-5D-5L, iPCQ, iMCQ&#xD;
1 week, 1 month, 3, 6 and 12 months after treatment</description>
    <arm_group_label>Non-Operative Management (NOM)/Observational</arm_group_label>
    <arm_group_label>Splenic Artery Embolization</arm_group_label>
    <arm_group_label>Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI abdomen</intervention_name>
    <description>Patients who were treated with splenic artery embolization will also undergo an MRI one month and one year after treatment.</description>
    <arm_group_label>Splenic Artery Embolization</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with splenic injury after blunt abdominal trauma confirmed by ultrasound&#xD;
        (US/FAST) and/or computed tomography (CT) at the primary trauma screening at the 5 selected&#xD;
        hospitals between March 2017 and December 2018 will be asked to participate in this study&#xD;
        as soon as they can talk and are lucid. Patients receive a verbal and written explanation&#xD;
        about the study. The time for consideration is one week. When a patient is willing to&#xD;
        participate he/she will be asked to sign a consent form. When patients agree to&#xD;
        participate, they are included for follow-up.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Splenic injury after blunt abdominal trauma (confirmed by FAST and/or CT)&#xD;
&#xD;
          -  The patient underwent NOM/SAE/splenectomy for the management of traumatic splenic&#xD;
             injury&#xD;
&#xD;
          -  The treatment took place in the period from March 2017 to December 2018 at one of the&#xD;
             five selected hospitals&#xD;
&#xD;
          -  18 years or older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Insufficient knowledge of the Dutch language&#xD;
&#xD;
          -  Patients who died during or after treatment are (of course) excluded for&#xD;
             questionnaires and MRI, not for clinical outcomes&#xD;
&#xD;
        Exclusion for MRI only:&#xD;
&#xD;
        - Patients treated with SAE: patients who do not want to or are not able to undergo an MRI&#xD;
        abdomen (for example pregnant women or other contraindications for MRI). Patients excluded&#xD;
        for MRI still need to fill out the questionnaires. Also, their clinical outcomes will be&#xD;
        processed in the database.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jolanda de Vries, Prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Project leader (ETZ Tilburg, Tilburg University)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital</name>
      <address>
        <city>Breda</city>
        <state>Noord-Brabant</state>
        <zip>4800 RL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth-Twee Steden Hospital</name>
      <address>
        <city>Tilburg</city>
        <state>Noord-Brabant</state>
        <zip>5000 LC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <state>Overijssel</state>
        <zip>7512 KZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala</name>
      <address>
        <city>Zwolle</city>
        <state>Overijssel</state>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Hospital</name>
      <address>
        <city>Dordrecht</city>
        <state>Zuid-Holland</state>
        <zip>3300 AK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasstad Hospital</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3007 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://www.zonmw.nl/nl/onderzoek-resultaten/kwaliteit-van-zorg/programmas/project-detail/topzorg/traumatic-splenic-injury-and-management/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://www.etz.nl/TopZorg/Behandeling-traumatisch-miltletsel</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 22, 2017</study_first_submitted>
  <study_first_submitted_qc>March 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

